Novartis' Q1 sales miss hints at industry's utilisation of M&A remedies [Yahoo! Finance]
(RNAM)
Company Research
Source: Yahoo! Finance
The Swiss drugmaker reported a 12% drop in profits to $4.9bn compared with the same period in 2025. The profit tumble came alongside a decline in net sales, which reached $13.1bn, 1% shy of the $13.2bn from Q1 2025. Novartis blamed US generic erosion, which, the company added, more than offset any growth drivers. No more was this felt than with blockbuster Entresto (sacubitril/valsartan), the company's heart failure medication that racked up $7.8bn in peak sales in 2025. It was a difficult Q1 for the drug this year, with sales plummeting 42% compared to the same quarter last year. Other drugs also suffered from generics market entry, including blood disorder medicine Promacta (eltrombopag) and blood cancer therapy Tasigna (nilotinib). On an earnings call, Novartis' chief financial officer Mukul Mehta admitted a difficult continuation of this year lies in wait. “H1 will be impacted by a tough previous year [baseline] following US generic entries,” Mehta commented. Novartis exp
Show less
Read more
Impact Snapshot
Event Time:
RNAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNAM alerts
High impacting news events
Weekly update
A roundup of the hottest topics
RNAM
Sec Filings
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- RNAM's page on the SEC website